When is a pre­clin­i­cal drug worth a moth­er lode of cash? This top 20 list of­fers a few an­swers

When Ver­tex is in­tent on a tar­get, the ex­ecs are known to splash out big time for ex­per­i­men­tal prod­ucts.

That gung-ho spir­it was on full dis­play in late 2022 when the biotech hand­ed over $250 mil­lion in cash for a pre­clin­i­cal DM1 treat­ment from En­tra­da Ther­a­peu­tics. In their Q1 re­port, Ver­tex would go on to say that the En­tra­da deal was part of $347 mil­lion spent on ac­quired IPR&D charges in the quar­ter.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.